Centre International De Recherches Dermatologiques Galderma

Nestec S.a.

Michel Demarchez

Andre Jomard

Patricia Rossio

Serge Michel

Andr&eacute; Jomard

Marie-Cecile Lenoir-Viale

Christine Cathelineau

Sylvie Pridmore-Merten

Emmanuelle Lurati

Farzaneh Pourzand-Azarmehr

The invention concerns tye use of a inhibitor of retinoic acid as sole ingredient in a pharmaceutical or cosmetic composition comprising administering effective amount of the composition to treat sensitive skin or skin damage induced by UV radiation.

Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation

The present invention relates to the use of at least one ligand which is specific for RXR receptors, in the preparation of a pharmaceutical composition to be administered systemically and intended to increase the cellular proliferation and/or differentiation modulatory activity of a ligand for at least one receptor of the superfamily of steroidal/thyroidal receptors, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with the RXRs, which is applied topically.

Use of ligands which are specific for RXR receptors

Use of inhibitors of retinoic acid activity for wound healing

The present invention relates to a process for identifying RAR-antagonist molecules, characterized in that it comprises the following steps: (i) a sufficient amount of an RAR-agonist molecule is applied topically to a part of the skin of a mammal, (ii) a molecule capable of having an RAR-antagonist activity is administered systemically or topically to this same mammal, or to this same part of the skin of the mammal, before, during or after step (i), and (iii) the response on that part of the skin of the mammal thus treated is evaluated.

Process for identifying RAR-receptor-antagonist compounds

Pharmaceutical/dermatological compositions comprising (a) at least one first ligand displaying selective activity for the RXR receptors and (b) at least one second ligand displaying selective activity for the RAR-.alpha. receptor, are useful for modulating the proliferation and/or differentiation of HL-60 type cells, in particular for the systemic treatment of acute promyelocytic leukemia.

Synergistic therapeutic compositions comprising at least one ligand

The present invention relates to a process for identifying RXR-agonist molecules, characterized in that it comprises the following steps: (i) a sufficient amount of a compound which is an active ligand for at least one receptor of the super-family of steroidal/thyroidal receptors, other than an RXR-receptor-specific ligand, and which can heterodimerize with the RXRs, is applied topically to a part of the skin of a mammal, (ii) a molecule capable of having an RXR-agonist activity is administered systemically or topically to this same mammal, or to this same part of the skin of the mammal, before, during or after step (i), and (iii) the response on that part of the skin of the mammal thus treated is evaluated.

Growing community of inventors

Le Bar sur Loup, France

Michel Demarchez